Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The subjects are being asked to take part in the Phase I or Phase II portion of a research
study of a new investigational drug, LBH589, in combination with chemotherapeutic agents,
carboplatin with etoposide. LBH589 (made by Novartis Pharmaceuticals Corp.) is considered
"investigational" because it has not been approved for commercial use in the treatment of
cancer by the U.S. Food and Drug Administration (FDA). Etoposide and carboplatin are
chemotherapeutic agents approved by the FDA for the treatment of for small cell lung cancer.
LBH589 is a drug that may slow down the growth of cancer cells or kill cancer cells by
blocking certain enzymes (proteins produced by cells). LBH589 has shown effects against
cancer in laboratory studies and in studies using animals; however, it is not known if this
medicine will show the same activity in humans. As of May 2006, approximately 100 patients
have received treatment with either an intravenous or capsule form of LBH589. Only the
capsule form of LBH589 will be used in this study.
The main goal during the Phase I portion of this research study is to find out the highest
and safest dose of LBH589 that can be given in combination with carboplatin with etoposide in
subjects with lung cancer without causing severe side effects. The main goal of the Phase II
portion of this study is to find how the subject's lung cancer responds to the LBH589 in
combination with carboplatin and etoposide at the highest and safest dose that was given in
Phase I.
The subject may be enrolled in either Phase I or Phase II of the trial, depending on when
they entered the study, but they will not be enrolled in both phases.
This study will also investigate how the subject's body processes the combination of LBH589
and carboplatin with etoposide. To determine this, the investigators will measure the amount
of study drug in the subject's blood. This will be done with a series of blood tests, called
pharmacokinetic (PK) tests. Pharmacokinetics is the study of how the study drug moves through
the body. Other purposes of this study will be to sample the subject's genetic material
(DNA/RNA) as well as to determine biomarkers in their blood. (For some cancers, biomarkers
are a way to measure the extent of their disease or the effects of treatment.) These samples
will also be stored for future studies.